With a market capitalization (market cap) of $2.05B — a measure of how much the company is worth — Replimune Group, Inc. ranks #1,952 among the 2,447 companies tracked, and 251st in Healthcare as of November 8, 2026. Shares trade at $21.62, up 7.99% on the day.
of 2,447 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 6, 2026. Ranking headline cap is the snapshot figure as of November 8, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Nov 6, 2026 | $2.27B | +153.77% | $21.62 |
| 2025 | Dec 31, 2025 | $896.06M | -8.16% | $9.72 |
| 2024 | Dec 31, 2024 | $975.63M | +73.65% | $12.11 |
| 2023 | Dec 29, 2023 | $561.82M | -64.30% | $8.43 |
Ranking figure $2.05B as of November 8, 2026.
Replimune Group, Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $21.62 as of November 6, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $2.27B on November 6, 2026. See how the ranking works.
The ranking snapshot ($2.05B as of November 8, 2026) is FMP company-screener market cap. The historical observation ($2.27B on November 6, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2026) used a weighted-average 92,803,711 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
Undefined when revenue is zero
Undefined when revenue is zero
Undefined when revenue is zero
FY 2026
FY 2026
Undefined when revenue is zero
FY 2026
Undefined when revenue is zero
FY 2026
FY 2026
FY 2026
FY 2026
Not in this snapshot
FY 2026 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.27T | -0.79% |
| #20 | Johnson & Johnson JNJ | $664.95B | +1.43% |
| #23 |
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2026.
Visit websiteAs of November 8, 2026, Replimune Group, Inc. (REPL) is worth $2.05B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2026, Replimune Group, Inc.’s book equity is about $166.16M. Market cap is the market value of the outstanding shares. As of November 8, 2026, its market cap is $2.05B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Replimune Group, Inc. ranks #1,952 among the 2,447 companies tracked on MarketCapLens. In Healthcare it ranks #251 of 352.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
| 2022 |
|---|
| Dec 30, 2022 |
| $1.57B |
| +22.67% |
| $27.20 |
| 2021 | Dec 31, 2021 | $1.28B | — | $27.10 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2026
| $514.78B |
| +1.07% |
| #30 | Merck & Co., Inc. MRK | $361.96B | -0.16% |
| #31 | UnitedHealth Group Incorporated UNH | $353.79B | -0.40% |
| #37 | Novartis AG NVS | $307B | +0.38% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #1949 | Vir Biotechnology, Inc. VIR | $2.07B | +10.80% |
| #1950 | Centrus Energy Corp. LEU | $2.06B | +17.49% |
| #1951 | Centuri Holdings, Inc. CTRI | $2.06B | +9.22% |
| #1953 | Globant S.A. GLOB | $2.05B | -3.72% |
| #1954 | Ducommun Incorporated DCO | $2.04B | +2.08% |
| #1955 | Trevi Therapeutics, Inc. TRVI | $2.04B | +11.87% |
Replimune Group, Inc.’s ranking market cap of $2.05B comes from the same snapshot as the rest of this site, as of November 8, 2026. It is not share price multiplied by the FY 2026 weighted-average share count of 92,803,711. The ranking snapshot ($2.05B as of November 8, 2026) is FMP company-screener market cap. The historical observation ($2.27B on November 6, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Over the past year, Replimune Group, Inc.’s market cap is up 190.19%, using historical market-cap records rather than today’s share count applied to past prices.
Replimune Group, Inc. (REPL) shares trade at $21.62, up 7.99% on the day, as of November 8, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.